Anbixun (Fuzhou) Medical Technology Co., Ltd. – Trademark Portfolio

Entity Type: 99

Anbixun (Fuzhou) Medical Technology Co., Ltd. holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include SERAPY. The owner is based in Taijiang, Fuzhou City.

No.108,Guangda Rd.,Chating St

Rm.07,08,F42,1#,Shimao Intl Center

Taijiang, Fuzhou City 350005 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

SERAPY
SERAPY
Registered 2023

Trademark Classifications

Anbixun (Fuzhou) Medical Technology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (1 filing)

Surgical, medical, dental and veterinary apparatus and instruments

Frequently Asked Questions

How many trademarks does Anbixun (Fuzhou) Medical Technology Co., Ltd. have?

Anbixun (Fuzhou) Medical Technology Co., Ltd. has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does Anbixun (Fuzhou) Medical Technology Co., Ltd. file in?

Anbixun (Fuzhou) Medical Technology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 10 (Medical Apparatus). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are Anbixun (Fuzhou) Medical Technology Co., Ltd.'s most well-known trademarks?

Anbixun (Fuzhou) Medical Technology Co., Ltd.'s registered trademark portfolio includes well-known marks such as SERAPY. These are among 1 currently registered trademark in the portfolio.

What is Anbixun (Fuzhou) Medical Technology Co., Ltd.'s trademark registration success rate?

Anbixun (Fuzhou) Medical Technology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.